



## Iveric Bio to Present at the 39th Annual J.P. Morgan Healthcare Conference

December 17, 2020

NEW YORK--(BUSINESS WIRE)--Dec. 17, 2020-- [IVERIC bio, Inc.](#) (Nasdaq: ISEE) announced today that Glenn P. Sblendorio, Chief Executive Officer and President, will present an overview of the Company at the 39<sup>th</sup> Annual J.P. Morgan Healthcare Conference in a [virtual session](#) on Thursday, January 14, 2021 at 2:50 p.m. Eastern Time.

Investors and the general public are invited to listen to a live webcast of the presentation on the Investor / Events & Presentations section of the IVERIC bio website at [www.ivericbio.com](http://www.ivericbio.com). An archived replay of the webcast will be available on the Company's website immediately following the conference and for at least two weeks thereafter.

### About IVERIC bio

IVERIC bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. The Company is currently developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inherited retinal diseases. Vision is Our Mission. For more information on the Company please visit [www.ivericbio.com](http://www.ivericbio.com).

### Forward-looking Statements

*Any statements in this press release about IVERIC bio's future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Any forward-looking statements represent IVERIC bio's views only as of the date of this press release. IVERIC bio anticipates that subsequent events and developments will cause its views to change. While IVERIC bio may elect to update these forward-looking statements at some point in the future, IVERIC bio specifically disclaims any obligation to do so.*

### ISEE-G

View source version on [businesswire.com](https://www.businesswire.com/news/home/20201217005168/en/): <https://www.businesswire.com/news/home/20201217005168/en/>

### Investors:

IVERIC bio  
Kathy Galante, 212-845-8231  
Vice President, Investor Relations and Corporate Communications  
[kathy.galante@ivericbio.com](mailto:kathy.galante@ivericbio.com)

or

### Media:

SmithSolve  
Alex Van Rees, 973-442-1555 ext. 111  
[alex.vanrees@smithsolve.com](mailto:alex.vanrees@smithsolve.com)

Source: IVERIC bio, Inc.